LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer HealthCare’s radium-223).
LaunchTrends®: Xofigo measures the impact of this new agent on the metastatic castrate-resistant prostate cancer (mCRPC) market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. These reports evaluate physicians’ current awareness and perception of Xofigo relative to other currently available therapies for mCRPC, current and anticipated use of Xofigo, and promotional activity of Xofigo.

Questions Answered in This Report:

  • What are physicians aided and unaided awareness of, and familiarity with, Xofigo?


  • To what extent is Xofigo currently being used among surveyed physicians?


  • Where is Xofigo expected to fit in the treatment algorithm for mCRPC?


  • What is surveyed physicians’ level of satisfaction with Xofigo?


  • What are Xofigo’s perceived advantages and disadvantages relative to other currently available therapies for mCRPC?


  • How will the complexities associated with prescribing a radiopharmaceutical impact Xofigo?


  • What promotional messages are being employed by Algeta/Bayer HealthCare?

Scope:

Sample Frame & Methodology:

~75 medical oncologists complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ~15 physicians participate in a 30-minute qualitative interview.

To qualify, surveyed respondents must meet the following criteria:

- Minimum of 25 prostate cancer patients under their personal management per month

- Minimum of 10 mCRPC patients under their personal management per month

- Have been in practice a minimum of 2 years and a maximum of 30 years

- More than 75% of professional time spent in clinical practice (academic hospital setting allowed 50% practice time)

Report Dates:

Wave 1: August 2013

Wave 2: February 2014

Wave 3: August 2014

Physician Research:

Medical Oncologists

Geographies:

United States

Key Drugs Covered:

Xofigo, Xtandi, Zytiga, Jevtana, Provenge, docetaxel

Key Comapnaies Mentioned:

- Algeta

- Bayer HealthCare

- Medivation

- Astellas Pharma

- Johnson & Johnson

- Sanofi

- Dendreon

Deliverables:

- Final report in powerpoint format

- Access to author

Related Reports and Products:

- TreatmentTrends®: Prostate Cancer US

- LaunchTrends®: Xtandi US

- Pharmacor®: Prostate Cancer

- DecisionBase®: Prostate Cancer (Metastatic Castrate Resistant)

- PatientBase®: Prostate Cancer in G7, Brazil, Russia, India, China, Mexico, Turkey, and South Korea

- Physician and Payer Forum® (US): Cancer Immunotherapeutics

- Physician and Payer Forum® (US): Payer-Imposed Strategies on Market Access in Non-Small-Cell Lung Cancer and Prostate Cancer

- Physician and Payer Forum® (EU5): The Dynamic Prostate Cancer Landscape

- Emerging Markets: Prostate Cancer in China


Related Reports

Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Access & Reimbursement - Detailed, Expanded Analysis (US)

The many premium-priced hormonal therapies for prostate cancer present a financial burden for payers. Moreover, costs are set to increase with the recent approvals of the LHRH antagonist Orgovyx fo...

View Details

Prostate Cancer | Disease Landscape and Forecast | G7 | 2020

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

View Details